567 related articles for article (PubMed ID: 26493961)
21. CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy.
Kühnöl C; Herbarth M; Föll J; Staege MS; Kramm C
Cancer Immunol Immunother; 2013 Dec; 62(12):1797-809. PubMed ID: 24129764
[TBL] [Abstract][Full Text] [Related]
22. CD8α+ DCs can be induced in the absence of transcription factors Id2, Nfil3, and Batf3.
Seillet C; Jackson JT; Markey KA; Brady HJ; Hill GR; Macdonald KP; Nutt SL; Belz GT
Blood; 2013 Feb; 121(9):1574-83. PubMed ID: 23297132
[TBL] [Abstract][Full Text] [Related]
23. CD137, an attractive candidate for the immunotherapy of lung cancer.
Ye L; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
Cancer Sci; 2020 May; 111(5):1461-1467. PubMed ID: 32073704
[TBL] [Abstract][Full Text] [Related]
24. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity.
Hildner K; Edelson BT; Purtha WE; Diamond M; Matsushita H; Kohyama M; Calderon B; Schraml BU; Unanue ER; Diamond MS; Schreiber RD; Murphy TL; Murphy KM
Science; 2008 Nov; 322(5904):1097-100. PubMed ID: 19008445
[TBL] [Abstract][Full Text] [Related]
25. T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.
Martinez-Forero I; Azpilikueta A; Bolaños-Mateo E; Nistal-Villan E; Palazon A; Teijeira A; Perez-Chacon G; Morales-Kastresana A; Murillo O; Jure-Kunkel M; Zapata JM; Melero I
J Immunol; 2013 Jun; 190(12):6694-706. PubMed ID: 23690480
[TBL] [Abstract][Full Text] [Related]
26. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ.
Dubrot J; Milheiro F; Alfaro C; Palazón A; Martinez-Forero I; Perez-Gracia JL; Morales-Kastresana A; Romero-Trevejo JL; Ochoa MC; Hervás-Stubbs S; Prieto J; Jure-Kunkel M; Chen L; Melero I
Cancer Immunol Immunother; 2010 Aug; 59(8):1223-33. PubMed ID: 20336294
[TBL] [Abstract][Full Text] [Related]
27.
Theisen DJ; Ferris ST; Briseño CG; Kretzer N; Iwata A; Murphy KM; Murphy TL
Cancer Immunol Res; 2019 Jan; 7(1):29-39. PubMed ID: 30482745
[TBL] [Abstract][Full Text] [Related]
28. Batf3-Dependent Dendritic Cells Promote Optimal CD8 T Cell Responses against Respiratory Poxvirus Infection.
Desai P; Tahiliani V; Abboud G; Stanfield J; Salek-Ardakani S
J Virol; 2018 Aug; 92(16):. PubMed ID: 29875235
[TBL] [Abstract][Full Text] [Related]
29. Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.
Kwong B; Gai SA; Elkhader J; Wittrup KD; Irvine DJ
Cancer Res; 2013 Mar; 73(5):1547-58. PubMed ID: 23436794
[TBL] [Abstract][Full Text] [Related]
30. An In Vitro Model That Predicts the Therapeutic Efficacy of Immunomodulatory Antibodies.
Dai M; Yip YY; Hellstrom I; Hellstrom KE
J Immunother; 2016 Oct; 39(8):298-305. PubMed ID: 27488724
[TBL] [Abstract][Full Text] [Related]
31. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.
Stagg J; Loi S; Divisekera U; Ngiow SF; Duret H; Yagita H; Teng MW; Smyth MJ
Proc Natl Acad Sci U S A; 2011 Apr; 108(17):7142-7. PubMed ID: 21482773
[TBL] [Abstract][Full Text] [Related]
32. Mevalonate Blockade in Cancer Cells Triggers CLEC9A
Xu F; Wang Z; Zhang H; Chen J; Wang X; Cui L; Xie C; Li M; Wang F; Zhou P; Liu J; Huang P; Xia X; Xia X
Cancer Res; 2021 Sep; 81(17):4514-4528. PubMed ID: 34266895
[TBL] [Abstract][Full Text] [Related]
33. Transcription factor Batf3 is important for development of CD8+ T-cell response against a phagosomal bacterium regardless of the location of antigen.
Patel R; Sad S
Immunol Cell Biol; 2016 Apr; 94(4):378-87. PubMed ID: 26567886
[TBL] [Abstract][Full Text] [Related]
34. Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells.
Dubrot J; Portero A; Orive G; Hernández RM; Palazón A; Rouzaut A; Perez-Gracia JL; Hervás-Stubbs S; Pedraz JL; Melero I
Cancer Immunol Immunother; 2010 Nov; 59(11):1621-31. PubMed ID: 20607237
[TBL] [Abstract][Full Text] [Related]
35. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-12 from CD103
Mittal D; Vijayan D; Putz EM; Aguilera AR; Markey KA; Straube J; Kazakoff S; Nutt SL; Takeda K; Hill GR; Waddell N; Smyth MJ
Cancer Immunol Res; 2017 Dec; 5(12):1098-1108. PubMed ID: 29070650
[TBL] [Abstract][Full Text] [Related]
37. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.
Fu C; Jiang A
Front Immunol; 2018; 9():3059. PubMed ID: 30619378
[TBL] [Abstract][Full Text] [Related]
38. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
Noji S; Hosoi A; Takeda K; Matsushita H; Morishita Y; Seto Y; Kakimi K
J Immunother; 2012 Jul; 35(6):460-72. PubMed ID: 22735804
[TBL] [Abstract][Full Text] [Related]
39. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.
Murillo O; Dubrot J; Palazón A; Arina A; Azpilikueta A; Alfaro C; Solano S; Ochoa MC; Berasain C; Gabari I; Pérez-Gracia JL; Berraondo P; Hervás-Stubbs S; Melero I
Eur J Immunol; 2009 Sep; 39(9):2424-36. PubMed ID: 19662633
[TBL] [Abstract][Full Text] [Related]
40. Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow.
Mayer CT; Ghorbani P; Nandan A; Dudek M; Arnold-Schrauf C; Hesse C; Berod L; Stüve P; Puttur F; Merad M; Sparwasser T
Blood; 2014 Nov; 124(20):3081-91. PubMed ID: 25100743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
